Recent events
Recent events tied to this brand in public sources.
Back to profile4 entries
2020
Crescita licenses Pliaglis commercialization and development in mainland China
Crescita Therapeutics announced an exclusive agreement with Juyou-Biotechnology for the commercialization and development of Pliaglis in mainland China. Juyou will handle clinical development and regulatory filings; the product could launch as early as 2023 if no additional studies are required.
2020
Crescita announces a $3.5 million credit facility with RBC
Crescita Therapeutics announced that it had secured a $3.5 million revolving demand operating credit facility with the Royal Bank of Canada. The facility's closing remained subject to steps required to grant RBC security over Crescita's receivables and inventories.
2020
Crescita announces a $3.5 million credit facility
Crescita Therapeutics announced a $3.5 million revolving demand operating credit facility with the Royal Bank of Canada after repaying its Knight Therapeutics loan. The facility's closing remained subject to granting RBC a first-ranking charge over Crescita's receivables and inventories.
2020
Crescita enters exclusive distribution agreement with FILLMED
Crescita Therapeutics announced that it had entered into an agreement with FILLMED for exclusive distribution in Canada of the ART-FILLER injectables range and NCTF products.